The Centers for Disease Control and Prevention loosened masking guidelines on Tuesday for outdoor activity. Among other changes, fully vaccinated people are no longer advised to wear masks outdoors when running or biking, unless in large groups. (The New York Times)

Biogen agreed to give a small group of ALS patients its experimental drug tofersen, after advocates pushed for the company to provide greater access to an ongoing trial. But the change may come too late to help Lisa Stockman Mauriello, the patient and Syneos Health executive who spearheaded the campaign. (STAT)

Eli Lilly announced it is dropping plans to develop mirikizumab, its once-promising psoriasis drug. In a statement, the company said it believes “the psoriasis market is well-served with our existing medicine, Taltz.” (Endpoints News)

Pfizer’s experimental oral pill that aims to treat COVID-19 may be available by the end of the year, CEO Albert Bourla said. The treatment is part of a class of drugs called protease inhibitors, which hinder an enzyme that the virus uses to replicate. (CNBC Weekly)

As COVID-19 sweeps across India, experts fear many cases are going unreported. India has reported more than 17 million cases since the beginning of the pandemic, but some experts believe the sum could be 30 times higher. (CNN)